Truncated CD200
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Apr 17, 2007
Grant Date -
Mar 18, 2004
app pub date -
Nov 22, 2001
filing date -
Nov 22, 2000
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
A truncated form of the full-length, immunosuppression-inducing molecule, CD200, CD200.sub.tr, was expressed in CHO cells and the transduced cells used to produce mAbs to CD200.sub.tr. These mAbs detect simultaneous expression of full-length CD200 and CD200.sub.tr in LPS-stimulated dendritic cells (DCs). Moreover, CHO cells and DCs expressing CD200.sub.tr as well as soluble CD200.sub.tr are able to inhibit suppression of mixed leucocyte reactions in vitro which follows addition of the soluble form of CD200 (CD200:Fc) in culture, demonstrating that CD200.sub.tr is a physiological antagonist of CD200.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully